Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Tilray Brands Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Tilray Brands Inc trades at $4.75 (market cap $601.34M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TLRY | |
|---|---|---|
Market Cap | $863.95M | $601.34M |
Sector | Health | Health |
52-Week High | $30.81 | $21.00 |
52-Week Low | $16.87 | $3.88 |
Enterprise Value | $1.26B | $768.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
TLRY trades at $4.57, up 2.93% with a bullish technical signal, though recent earnings misses and negative profitability metrics highlight fundamental challenges. The company reported record fiscal 2026 revenue of $915 million but continues to post significant net losses. Analyst sentiment is mixed with 25% buy ratings, while technical indicators show RSI near overbought levels with key support at $4.
Outlook remains cautious due to persistent losses and high valuation multiples, though revenue growth and diversification into beverages offer potential upside. Key risks include execution challenges, cannabis regulatory uncertainty, and competitive pressures in the consumer goods space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
